Last reviewed · How we verify

Teriflunomide HMR1726 — Competitive Intelligence Brief

Teriflunomide HMR1726 (Teriflunomide HMR1726) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydroorotate dehydrogenase inhibitor; immunosuppressant. Area: Immunology; Neurology.

marketed Dihydroorotate dehydrogenase inhibitor; immunosuppressant Dihydroorotate dehydrogenase (DHODH) Immunology; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Teriflunomide HMR1726 (Teriflunomide HMR1726) — Sanofi. Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Teriflunomide HMR1726 TARGET Teriflunomide HMR1726 Sanofi marketed Dihydroorotate dehydrogenase inhibitor; immunosuppressant Dihydroorotate dehydrogenase (DHODH)
Teriflunomide Oral Tablet Teriflunomide Oral Tablet Oslo University Hospital phase 3 Immunosuppressant; dihydroorotate dehydrogenase inhibitor Dihydroorotate dehydrogenase (DHODH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydroorotate dehydrogenase inhibitor; immunosuppressant class)

  1. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teriflunomide HMR1726 — Competitive Intelligence Brief. https://druglandscape.com/ci/teriflunomide-hmr1726. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: